Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672474 | 0.85 | POLB (0.50) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL12106760 | 0.84 | MAPT (0.45) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL12963409 | 0.80 | CYP1A2 (0.47) | CYP1A2LMNAALDH1A1 | |
| SCHEMBL11359398 | 0.80 | MAPT (0.39) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL19687211 | 0.79 | S1PR2 (0.32) | S1PR2ALDH1A1 | |
| SCHEMBL10102118 | 0.79 | HSP90AB1 (0.36) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL11419164 | 0.77 | POLB (0.33) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL3473073 | 0.76 | TDP1 (0.76) | MAPTTDP1LMNAADORA1ALDH1A1 | |
| SCHEMBL7934015 | 0.76 | PGK1 (0.35) | POLBMAPTCACNA1BAPBA1PDE4A | |
| SCHEMBL13111256 | 0.74 | TDP1 (0.53) | MAPTCYP2C19TDP1LMNAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0124810-B1 | NEW PYRIMIDINE DERIVATIVES ENDOWED WITH ANTIVIRAL ACTIVITY | Gatti, Daniele (IT) | 1987-04-01 | — | — | EP | claimed |
| US-4629729-A | Endowed with anti-viral activity 2-alkylamino-4,6-dihalo pyrimidines | GATTI DANIELE (IT) | 1986-12-16 | — | — | US | claimed |
| EP-0124810-A1 | New pyrimidine derivatives endowed with antiviral activity | Gatti, Daniele (IT) | 1984-11-14 | — | — | EP | claimed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| WO-2020206080-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2536410-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-5998665-A | THERAPY FOR NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5939451-A | INDOL-4-YL-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5932599-A | 4-AMINO-N-(PYRIDINYL-4-YL)-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-03 | — | — | US | disclosed |
| CN-1170574-A | Sulfonamides and their use | HOFFMANN LA ROCHE (CH) | 1998-01-21 | — | — | CN | disclosed |
| EP-0815861-A1 | Sulphonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| EP-0124810-B1 | NEW PYRIMIDINE DERIVATIVES ENDOWED WITH ANTIVIRAL ACTIVITY | Gatti, Daniele (IT) | 1987-04-01 | — | — | EP | disclosed |
| US-4629729-A | Endowed with anti-viral activity 2-alkylamino-4,6-dihalo pyrimidines | GATTI DANIELE (IT) | 1986-12-16 | — | — | US | disclosed |
| EP-0124810-A1 | New pyrimidine derivatives endowed with antiviral activity | Gatti, Daniele (IT) | 1984-11-14 | — | — | EP | disclosed |
| US-RE31136-E | Herbicidal 5-pyrimidinecarbonitriles | FMC CORPORATION (US) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | POLB 4041/4885MAPT 4171/4885CACNA1B 4596/4885 |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | POLB 1390/4885MAPT 2570/4885CACNA1B 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.